Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers
Open accessPublished version of a preprint
The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index; 15 of the 47 sources its claims cite were checked for support.
Abstract
As microbial therapeutics are increasingly being tested in diverse patient populations, it is essential to understand the host and environmental factors influencing the microbiome. Through analysis of 1,359 gut microbiome samples from 946 healthy donors of the Milieu Intérieur cohort, we detail how microbiome composition is associated with host factors, lifestyle parameters, and disease states. Using a genome-based taxonomy, we found biological sex was the strongest driver of community composition. Additionally, bacterial populations shift across decades of life (age 20–69), with Bacteroidota species consistently increased with age while Actinobacteriota species, including Bifidobacterium, decreased. Longitudinal sampling revealed that short-term stability exceeds interindividual differences. By accounting for these factors, we defined global shifts in the microbiomes of patients with non-gastrointestinal tumors compared with healthy donors. Together, these results demonstrated that the microbiome displays predictable variations as a function of sex, age, and disease state. These variations must be considered when designing microbiome-targeted therapies or interpreting differences thought to be linked to pathophysiology or therapeutic response.
Overview
CoChat Summary
TL;DR
Byrd et al. profile the gut microbiome in 946 healthy French donors using 1,359 shotgun metagenomic samples and show that age and sex are major correlates of community composition. They also find that patients with non-gastrointestinal cancers have altered gut communities, including higher Bacteroidota/Firmicutes_A ratios and lower Shannon diversity than healthy donors.
Key findings
- Among 154 metadata variables, 52 were associated with species-level Bray–Curtis composition (PERMANOVA FDR < 0.05), with age and sex the top contributors; together these factors explained <10% of population variability. Age and sex were themselves associated with 44 and 24 other metadata variables, respectively.
- Sex differences included 71 differentially abundant species (FDR < 0.05), with 5 more abundant in females and 18 more abundant in males at log2 fold change >1; 11 of 32 prevalent *Prevotella* species were more abundant in males, and the creatinine degradation I pathway was most strongly enriched in men.
- Age was associated with 192/485 abundant species (FDR < 0.05), including increased Bacteroidota and decreased Actinobacteriota, with 15 *Bifidobacterium* species declining with age; 108 prevalent pathways correlated with age (31 increased, 77 decreased), including decreased lactose/galactose degradation pathways.
- In 413 donors sampled 17 ± 3.3 d apart, intraindividual differences were smaller than interindividual differences, but stability varied; baseline Shannon diversity was positively associated with stability (FDR = 0.014), while BMI and circulating triglycerides were negatively associated and sweet items and raw fruit positively associated (P < 0.05).
- Across 375 samples from 283 patients with non-GI cancers in five cohorts, cancer patients had increased Bacteroidota/Firmicutes_A ratios and decreased Shannon diversity versus healthy donors; on checkpoint inhibitor treatment they were on average more stable than MI donors, and several Enterobacteriaceae species were more prevalent.
Methods
- The Milieu Intérieur cohort included 946 healthy French donors (originally 500 women and 500 men, 20–69 yr) with 1,359 shotgun metagenomic samples; 413 donors provided longitudinal samples 17 ± 3.3 d apart. Metadata included 154 curated demographic, clinical, and dietary variables.
- A custom Kraken2/Bracken pipeline was built using 23,505 RefSeq genomes with Genome Taxonomy Database (GTDB) taxonomy; HUMANn2 was used for MetaCyc pathway profiles. The pipeline was also applied to an Israeli cohort (1,159 samples/851 donors), five non-GI cancer cohorts (375 samples/283 patients), and IBD cohorts.
- Analyses included PERMANOVA/adonis, DESeq2, Spearman correlations, generalized linear models, beta regression, Bray–Curtis and Jaccard distances, with Benjamini–Hochberg FDR correction; one baseline sample per donor was used except for longitudinal analyses.
Limitations
- The paper states that the cross-sectional design makes it difficult to disentangle age associations from variables correlated with age, and that Bristol stool score and chromogranin A levels were absent. It also notes that cancer analyses lacked extensive metadata, had batch effects across cohorts, and could not separate cancer itself from lifestyle changes or therapies; attempts to associate PC1/PC2 with therapy response were unsuccessful and response definitions varied.
- Evident from the text: the healthy cohort was restricted to self-reported metropolitan French origin, ages 20–69, BMI 18.5–32 kg/m², and stringent health exclusions, limiting generalizability. Cancer cohorts were heterogeneous across studies, with missing age/sex data for some patients and technical/geographic differences that could affect comparisons.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








![Figure 5. Bifidobacterium species and Bifidobacterium-associated pathways decrease with age. (A) Lines indicate the percent prevalence of 15 Bifidobacterium species across the different decades. Only Bifidobacterium species significantly associated with age are shown. (B) Boxplots show richness of Bifidobacterium species in donors grouped by their age. (C) Correlation plot of Bifidobacteria species (prevalence >30%) and their cocorrelated Collinsella species (Spearman ρ > 0.4). (D) 15 Bifidobacterium species were associated with age across cohorts. Left: Correlation of species with age (Spearman ρ). Middle: FDR value. Notably, even when a species was significant in only one cohort, the trend was consistent in the other. Right: Prevalence of each species. Color indicates the cohort. (E) Abundance (counts per million [CPM]) of lactose/galactose degradation pathways decreased with age. Curves show 95% confidence intervals and were modeled with LOESS regression. (F) Abundance (CPM) of l-histidine degradation/synthesis pathways associated with age. Curves show 95% confidence intervals and were modeled with LOESS regression. (G) For the pathways correlated with age in E and F, in the scatter plot, dots represent the species that were significantly correlated with that pathway. Of those, species that were also significantly correlated with age are colored by their phyla label. Species not associated with age are colored gray. Size of the point corresponds to the −log10(FDR) of the species by age correlation. See also Data S1, tables 12–14.](https://figures.cochat.ai/paper-figures/a52f32f305c64689845008dc6f6ee428/gut-microbiome-stability-and-dynamics-in-healthy-donors-and-patients-with-non-figure-5.jpg)





Verification
Claims the paper makes
9 Valid · 1 Not valid · 26 Not checked · 89 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The top contributors were age and sex, with lesser contributions from diet, such as consumption of raw fruit and cooked and cured meats, as well as frequency of fast food consumption, in line with previous reports of 16S rRNA analyses from this cohort (Partula et al., 2019; Scepanovic et al., 2019).”
§ Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers > Results > Variable gut microbiomes in a restricted geographical region
What the sources say
- Not checked yetcites Partula et al., 2019 source
- Partly supportedcites Scepanovic et al., 2019 sourceExperimental — accuracy not yet measured
The Results (Associations of non-genetic variables with gut microbiome parameters; page not available) identify age and sex as explaining the largest portions of variance in β-diversity and report a smaller significant association for raw-fruit consumption. The paper does not establish cooked or cured meats as contributors, and fast-food eating appears only in univariate α-diversity results, not among the factors retained for microbiome composition. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lower levels of lactose/galactose degradation may explain increased lactose intolerance in older adults and presents a possible opportunity for microbial therapeutic intervention (Gingold-Belfer et al., 2020; Savaiano et al., 2013).”
§ Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers > Results > The gut microbiome is dynamic across decades of life
What the sources say
- Not checked yetcites Gingold-Belfer et al., 2020 source
- Partly supportedcites Savaiano et al., 2013 sourceExperimental — accuracy not yet measured
The Introduction (p. n/a) and Discussion of Savaiano et al. 2013 support the mechanistic/therapeutic half of the claim: lactose maldigestion arises when small-bowel lactase falls, undigested lactose reaches the colon, and colonic adaptation 'includes the selection of a higher diversity and concentration of lactose-metabolizing species of bacteria, induction of microbial beta-galactosidase' — the basis for the RP-G28 galacto-oligosaccharide (microbial) intervention tested in the trial. However, nothing in our copy ties lower lactose/galactose degradation to 'older adults': the paper states the lactase reduction 'typically begins early in childhood' and is 'genetically-controlled', and the trial enrolled adults aged 18 to 64, with no age-related decline in degradation discussed. The older-adult attribution rests on the co-cited Gingold-Belfer et al. 2020, not on this source. (LLM, conf=0.72)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Despite this, medication usage was a significant, albeit minor, contributor (R2 = 0.003) to microbial community composition, highlighting how xenobiotics can and do influence the gut microbiome (Jackson et al., 2018; Maier et al., 2018).”
§ Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers > Results > Variable gut microbiomes in a restricted geographical region
What the sources say
- Partly supportedcites Jackson et al., 2018 sourceExperimental — accuracy not yet measured
The Results section, “Gut microbiota associations with common medications” (page unavailable), reports significant associations between medication use and microbiota markers for 19 of 52 medications. It does not report R² = 0.003 or quantify medication use as a minor contributor to overall microbial community composition. The paper also cautions that the associations may reflect disease-related effects rather than medication action. (LLM, conf=0.88)
- Partly supportedcites Maier et al., 2018 sourceExperimental — accuracy not yet measured
The Introduction (page not provided) says medication use has been associated with changes in gut microbiome composition, and the Discussion reports drug effects on gut bacteria. Neither passage gives R² = 0.003 or establishes that medication use is a statistically significant but minor contributor to community composition. (LLM, conf=0.86)
plainstates an associationn = 266- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Across measures (Fig. S4, F–I), patients in the Frankel et al. (2017) cohort were closer to healthy donors than patients in the other cancer cohorts.”
§ Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers > Results > Across cohorts, patients with non-GI cancers have altered gut microbial communities
What the sources say
- Supportedcites Frankel et al., 2017 source
The citation identifies the cohort used in the citing paper’s comparison, rather than attributing the healthy-donor comparison to Frankel et al. The Introduction describes a cohort of 39 metastatic melanoma patients whose fecal samples were analyzed for gut microbiota and metabolites. No page number is available in our copy. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Additionally, many species known to be present in yogurt and probiotics were also highly unstable, e.g., Lactobacillus_D sakei, Lactococcus lactis, and B. animalis (Fig. 6 G; Fijan, 2014)”
§ Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers > Results > Short-term stability is variable across donors
What the sources say
- Supportedcites Fijan, 2014 source
Sections 4.1, 4.2 and 4.4 identify L. sakei, B. animalis and Lactococcus lactis, respectively, in the review’s discussion of fermented-food or probiotic microorganisms. The sentence attributes the instability finding to its own Fig. 6G; Fijan (2014) supports the identification of the organisms, not that finding. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
60 more claims
Create a free account to see all 125 claims and to verify the 30 references still open.
- Probably not a substantial claim. 35
- It may state two separate claims as one. 32
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The P-ESC was considered representative of baseline microbiome data due to observations that the microbiome of patients treated with anti-PD-1, unlike anti-CTLA-4 or chemotherapy, is stable early after therapy initiation17–19.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers > Results > The gut microbiome is dynamic across decades of life
“the abundance of these pathways was not associated with consumption of dairy products, e.g., milk, cheese, and yogurt”
§ Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers > Results > The gut microbiome is dynamic across decades of life
“(Spearman ρ > 0.3).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers > Materials and methods > Experimental model and subject details
“correlated with another variable (Spearman ρ greater than −0.6 or < 0.6)”
§ Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers > Materials and methods > Experimental model and subject details
“154 metadata variables were considered for future correlations.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“In the end, we obtained 21 trillion raw paired-end reads from 1,359 samples from 946 of the donors. On average per sample, there were 2.4 Gbp, 15.5 million reads, with 358-bp insert size.”
§ Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers > Materials and methods > Details
Reported 21000000 · recomputed 21064.5
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers > Materials and methods > Quantification and statistical analysis
“Similarly, 1 − the Jaccard index was used to determine pathway stability based on presence/absence.”
§ Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers > Materials and methods > Quantification and statistical analysis
“Individuals with a stability of 1 had samples that were identical across time points, while a stability of 0 meant the samples were nothing alike.”
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 9×
“tween males/females and cancer patients/healthy donors, we input raw counts into DESeq2 (Love et al., 2014).”
InfluentialTrimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548 · cited 1×
“36 (Bolger et al., 2014); low-quality and low-complexity reads were removed with prinseq-lite 0.20.4 (Schmieder and Edwards, 2011); and Bowtie2 v2.”
MethodInfluentialFast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400 · cited 2×
“1.0 (Langmead and Salzberg, 2012) was used to remove reads mapping to PhiX or the PacBio human genome (parameters specified in Fig.”
MethodInfluentialWickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 33,115
Irizarry, R. (2019) · Introduction to Data Science · doi:10.1201/9780429341830-7 · Cited by 28,090 · cited 1×
“The majority of figures were rendered with ggplot2 (Wickham, 2016), adjusted with geasy (Carroll et al., 2020), and arranged with cowplot (Wilke, 2019).”
BackgroundlmerTest Package: Tests in Linear Mixed Effects Models
Kuznetsova, A., Brockhoff, P. B., & Christensen, R. H. B. (2017) · Journal of Statistical Software · doi:10.18637/jss.v082.i13 · Cited by 24,346
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Brooks, M., Kristensen, K., Benthem, K., Magnusson, A., Berg, C., Nielsen, A., Skaug, H., Mächler, M., & Bolker, B. (2017) · The R Journal · doi:10.32614/rj-2017-066 · Cited by 12,915
Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4_9 · Cited by 12,516
Cited by
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
“There are evidently organ/tissue-specific differences in the constitution of the associated microbiomes in homeostasis, aging, and cancer, with both overlapping and distinctive species and abundancies to that of the colon (104, 105).”
BackgroundMcCulloch, J. A., Davar, D., Rodrigues, R. R., Badger, J. H., Fang, J. R., Cole, A. M., Balaji, A. K., Vetizou, M., Prescott, S. M., Fernandes, M. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01698-2 · Cited by 472
Causal relationship between gut microbiota and cancers: a two-sample Mendelian randomisation study
Long, Y., Tang, L., Zhou, Y., Zhao, S., & Zhu, H. (2023) · BMC Medicine · doi:10.1186/s12916-023-02761-6 · Cited by 401
“Actinobacteria, including 15 species of Bifidobacterium, decreased with age, and the overall richness or number of unique Bifidobacterium species present in an individual steadily declined throughout their life [38].”
BackgroundTargeting the gut microbiota for cancer therapy
Fernandes, M. R., Aggarwal, P., Costa, R. G. F., Cole, A. M., & Trinchieri, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00513-x · Cited by 290
Human immune diversity: from evolution to modernity
Liston, A., Humblet-Baron, S., Duffy, D., & Goris, A. (2021) · Nature Immunology · doi:10.1038/s41590-021-01058-1 · Cited by 187
Self-citation
Metadata
- Authors
- Byrd, A. L., Liu, M., Fujimura, K. E., Lyalina, S., Nagarkar, D. R., Charbit, B., Bergstedt, J., Patin, E., Harrison, O. J., Quintana-Murci, L., Mellman, I., Duffy, D., Albert, M. L., & the Milieu Intérieur Consortium
- Affiliations
- Genentech (US)
- Institut Pasteur (FR)
- Centre National de la Recherche Scientifique (FR)
- Human Evolutionary Genetics Unit, Institut Pasteur, UMR 2000, Centre National de la Recherche Scientifique, Paris, France 5
- Benaroya Research Institute (US)
- insitro, inc. (United States) (US)
- Corresponding author
- Byrd, Allyson L.
- Duffy, Darragh
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2020-11-11
- Volume
- 218
- Issue
- 1
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC7664509
- OpenAlex
- W3098540694
- Cited by
- 63
- References
- 82
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 12 · 2023: 10 · 2022: 14 · 2021: 10
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, other-oa)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- Funders
- French government
- Agence Nationale de la Recherche (ANR-10-LABX-69-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Physical Sciences › Environmental Science › Ecology › Microbial Community Ecology and Physiology
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Keywords
- gut microbiota, microbiome stability, microbiome dynamics, sex differences, Bacteroidetes, Actinobacteriota, Bifidobacterium, host factors, lifestyle factors, microbiome-targeted therapy
- MeSH terms
- Gastrointestinal Microbiome, Adult, Aged, Bifidobacterium, Female, Humans, Male, Middle Aged, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers. https://app.cochat.ai/papers/10.1084/jem.20200606
- The paper
- Byrd, A. L., Liu, M., Fujimura, K. E., Lyalina, S., Nagarkar, D. R., Charbit, B., Bergstedt, J., Patin, E., Harrison, O. J., Quintana-Murci, L., Mellman, I., Duffy, D., Albert, M. L., & the Milieu Intérieur Consortium. (2021). Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20200606
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.